Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer.
Han LiuLiwen ZouNan XuHaiyun ShenYu ZhangPeng WanBaojie WenXiaojing ZhangYuhong HeLuying GuiWen-Tao KongPublished in: NPJ breast cancer (2024)
This study aimed to develop and validate a deep learning radiomics nomogram (DLRN) for the preoperative evaluation of axillary lymph node (ALN) metastasis status in patients with a newly diagnosed unifocal breast cancer. A total of 883 eligible patients with breast cancer who underwent preoperative breast and axillary ultrasound were retrospectively enrolled between April 1, 2016, and June 30, 2022. The training cohort comprised 621 patients from Hospital I; the external validation cohorts comprised 112, 87, and 63 patients from Hospitals II, III, and IV, respectively. A DLR signature was created based on the deep learning and handcrafted features, and the DLRN was then developed based on the signature and four independent clinical parameters. The DLRN exhibited good performance, yielding areas under the receiver operating characteristic curve (AUC) of 0.914, 0.929, and 0.952 in the three external validation cohorts, respectively. Decision curve and calibration curve analyses demonstrated the favorable clinical value and calibration of the nomogram. In addition, the DLRN outperformed five experienced radiologists in all cohorts. This has the potential to guide appropriate management of the axilla in patients with breast cancer, including avoiding overtreatment.
Keyphrases
- lymph node metastasis
- lymph node
- newly diagnosed
- deep learning
- end stage renal disease
- sentinel lymph node
- ejection fraction
- neoadjuvant chemotherapy
- chronic kidney disease
- healthcare
- artificial intelligence
- peritoneal dialysis
- machine learning
- ultrasound guided
- prognostic factors
- patients undergoing
- convolutional neural network
- early stage
- computed tomography
- emergency department
- magnetic resonance
- patient reported
- locally advanced
- contrast enhanced
- low cost
- rectal cancer